Tareq Kass-Hout, MD
Cramer SC, Abila B, Scott NE, Simeoni M, Enney LA, on behalf of the MAG111539 study investigators. Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke. Stroke. 2013
In a study recently published online in Stroke, Cramer and colleagues are proposing the monoclonal antibody (GSK249320) as a neurobiology modulator of human brain repair system after stroke. Promising results were reported in the past about the potential benefit of restorative therapies in reducing disability and improving outcomes in stroke patients. This study was the first to objectively evaluate the safety and tolerability of these antibodies and its translation in a better motor function.
This is a small prospective Cohort of 42 patients with mild-moderate stroke showed randomized to IV (GSK249320) (1,5 or 15 mg/kg per infusion) vs. Placebo. After 112 days of follow up, that monoclonal antibodies (GSK249320) in escalating doses had no safety concerns compared to placebo. Global outcome measures were similar across all groups. Moreover, one of the functional outcomes (gait velocity) showed a trend towards improvement with monoclonal antibodies.
This novel approach to brain repair after stroke with monoclonal antibodies infusion support the safety and tolerability of this pharmaceutical compound. Future studies might explore this efficacy as a restorative therapy for stroke.